3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
4
Recruiting
2
Not yet recruiting
2
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
1476
Neoplasms
999
Colorectal Neoplasms
830
Carcinoma, Non-Small-Cell Lung
724
Carcinoma, Hepatocellular
683
Stomach Neoplasms
647
Lung Neoplasms
584
Prostatic Neoplasms
543
Pancreatic Neoplasms
456
Rectal Neoplasms
338
Uterine Cervical Neoplasms
303
Colonic Neoplasms
295
Neoplasm Metastasis
292
Ovarian Neoplasms
285
Esophageal Neoplasms
279
Recurrence
278
Leukemia, Myeloid, Acute
253
Head and Neck Neoplasms
241
Multiple Myeloma
232
Brain Neoplasms
204
Polycystic Ovary Syndrome
200
Nasopharyngeal Carcinoma
198
Melanoma
198
Precursor Cell Lymphoblastic Leukemia-Lymphoma
195
Urinary Bladder Neoplasms
193
Lymphoma
178
Liver Neoplasms
178
Endometrial Neoplasms
159
Motor Activity
147
Lymphoma, Large B-Cell, Diffuse
141
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
OTHER
×
Tertiary Lymphoid Structures
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled